Wednesday, October 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analyst Ratings

Seagen Inc.: Investing in the Future of Cancer Treatment

Roberto by Roberto
July 2, 2023
in Analyst Ratings
0
USB stock news
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

The healthcare industry is a constantly evolving field, with new developments and innovations occurring at an often staggering pace. One biotechnology company that has been making waves in this space is Seagen Inc. (NASDAQ:SGEN), which develops and commercializes therapies for the treatment of cancer in the United States and internationally.

But what does the future hold for Seagen? According to a recent filing with the SEC, Winthrop Advisory Group LLC lessened its holdings in shares of Seagen by 49.3% in the first quarter of 2023. This news may come as a surprise to some, but it’s important to note that it’s just one piece of the puzzle when it comes to understanding what’s happening with the company.

Despite this decrease in holdings, Seagen remains a highly regarded entity within the industry. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

Additionally, a number of equities research analysts continue to issue reports on Seagen despite any fluctuations in its stock performance. For instance, SVB Securities recently boosted their target price on Seagen from $141.00 to $229.00 in a research report conducted on March 14th; Truist Financial followed suit by increasing their target price on Seagen from $152.00 to $229.00 later that month; and Berenberg Bank lowered their rating on Seagen from “buy” to “hold” in March as well.

Overall, it seems that while some investors may be lessening their holdings in Seagen, the company continues to garner attention and positive reviews from industry experts. The healthcare field remains complex, but companies like Seagen are poised to have a strong impact on the future of patient care.
[bs_slider_forecast ticker=”SGEN”]

Seagen Secures Substantial Investments from Institutional Investors and Hedge Funds for Cancer Treatment Development

[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”SGEN” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]



Seagen, a leading biotechnology company that specializes in cancer treatment, has recently announced significant investments made by institutional investors and hedge funds. The company’s stock has increased significantly over the past few quarters, with shares currently trading at $198.22 on NASDAQ.

According to reports, Stonnington Group LLC invested $631,000 in Seagen during the first quarter of 2023. Raymond James & Associates raised its stake in Seagen by 0.5% in the same period and now owns 29,655 shares of the company’s stock worth $6,004,000. Additionally, Yarbrough Capital LLC raised its stake in Seagen by 87.3% and now owns 4,526 shares of the stock worth $916,000.

Institutional investors and hedge funds own approximately 81.88% of Seagen’s overall stock value.

The news comes as the company continues to make a name for itself within the pharmaceutical industry for developing life-saving drugs to battle cancer. Seagen’s current range includes ADCETRIS – an antibody-drug conjugate for Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV – an ADC targeting Nectin-4 for urothelial cancer; and TUKYSA – an oral small molecule tyrosine kinase inhibitor intended for patients with advanced unresectable or metastatic HER2-positive breast cancer.

Despite being amid challenging circumstances due to Covid-19 pandemic which had severe effects on drug testing procedures across North America and Europe over last year increasing pandemic vaccination supply will show immense changes this time ahead that is going to help biomedical sector towards developing more effective medicine especially like cancer.

Over the last year (2022), Seagen reported negative earnings per share (EPS) but remains hopeful for forthcoming years with progress been noted consistently to broaden suitable treatments geared toward those combating different types of cancers prevalent across globally.

Tags: SGEN
Roberto

Roberto

Related Posts

RLI stock news
Analyst Ratings

Growing Interest in Pentair plc: Institutional Investor Acquires Stake, CEO Sells Shares

September 14, 2023
SNDR stock news
Analyst Ratings

Douglass Winthrop Advisors LLC Increases Stake in Canadian National Railway as Company Announces Quarterly Dividend Increase

September 14, 2023
FITB stock news
Analyst Ratings

Investment Firm Reduces Holdings in Mettler-Toledo International Despite Strong Q2 Earnings

September 14, 2023
Next Post
VCIT stock news

Stonnington Group LLC Invests in Apellis Pharmaceuticals, Inc.: A Promising Biopharmaceutical Investment Opportunity

BMY stock news

Vishria Bird Financial Group LLC Invests in Meta Platforms, Formerly Known as Facebook

MMP stock news

Hennessy Advisors Inc. Reduces Stake in Hingham Institution for Savings by 53.3%, Causing Market Concerns

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

Upstart Holdings Stock

Upstart Holdings Shares Slide Despite Impressive Quarterly Performance

4 weeks ago
Oracle Stock

Oracle’s AI Ambitions Fueled by Unprecedented $300 Billion Partnership

1 month ago
Uranium Energy Stock

US Uranium Producer Positions for Energy Independence Push

1 month ago
Synopsys Stock

Synopsys Shares Plunge Amid Customer Crisis and Earnings Disappointment

4 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

The iShares MSCI World ETF: Navigating a Crossroads of Concentration and Market Volatility

Microsoft CEO’s Compensation Reaches Historic High Amid Strong Financial Performance

The Hydrogen Conundrum: Why Plug Power’s Operational Wins Aren’t Translating to Market Gains

Strategy’s Bold Bitcoin Bet: $19 Million Purchase and Citi’s Bullish Call

Viking Therapeutics Approaches Critical Juncture with Obesity Treatment Strategy

Regulatory Storm Clouds Gather Over Applovin

Trending

Bayer AG Stock
Analysis

Bayer Shares: When Will the Legal Storm Subside?

by Dieter Jaworski
October 22, 2025
0

Bayer shareholders face renewed pressure as another court ruling delivers a substantial blow. A $600 million damages...

SAP Stock

SAP’s Q3 Earnings: A Pivotal Moment for the Stock

October 22, 2025
MP Materials Stock

MP Materials Shares Plunge Following Senior Executive Stock Sale

October 22, 2025
iShares MSCI World ETF Stock

The iShares MSCI World ETF: Navigating a Crossroads of Concentration and Market Volatility

October 22, 2025
Microsoft Stock

Microsoft CEO’s Compensation Reaches Historic High Amid Strong Financial Performance

October 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Bayer Shares: When Will the Legal Storm Subside?
  • SAP’s Q3 Earnings: A Pivotal Moment for the Stock
  • MP Materials Shares Plunge Following Senior Executive Stock Sale

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com